BRAF and melanoma: Moreover, it was reported that BRAFV600E-driven melanoma cells were less sensitive to mTORC1 inhibitor-mediated autophagy induction (e.g., via rapamycin), suggesting a greater therapeutic benefit for combined inhibition of PI3K→AKT→mTOR signaling plus autophagy in non-BRAF-mutated melanoma cells [114].